Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Clover Biopharmaceuticals Ltd. ( (HK:2197) ) has provided an announcement.
Clover Biopharmaceuticals Ltd. announced its interim results for the six months ended June 30, 2025, reporting a decrease in cash and bank balances due to loan repayments and ongoing R&D investments. Despite a reduction in expenses and improved operational efficiency, the company recorded a loss of RMB101.3 million, attributed to the absence of non-recurring income from the previous year.
The most recent analyst rating on (HK:2197) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Clover Biopharmaceuticals Ltd. stock, see the HK:2197 Stock Forecast page.
More about Clover Biopharmaceuticals Ltd.
Clover Biopharmaceuticals Ltd. is a company operating in the biopharmaceutical industry, primarily focusing on the development and commercialization of vaccines and biologics, with a particular emphasis on respiratory vaccine candidates.
Average Trading Volume: 7,299,281
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.14B
See more data about 2197 stock on TipRanks’ Stock Analysis page.